Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
Authors:
- 12 February 2024
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (6) , 358-363
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Australia
- Sanofi-Aventis US LLC
This publication has 42 references indexed in Scilit:
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trialThe Lancet Haematology, 2020
- Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositisMedicine, 2020
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyThe Lancet, 2019
- Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology BiologicsFuture Oncology, 2019
- The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaClinical Cancer Research, 2019
- Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysisCurrent Medical Science, 2018
- Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)Annals of Oncology, 2017
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyThe Lancet Oncology, 2011